Reference
Reference TypeLiterature
TitleDesign of immunogenic peptides from Mycobacterium tuberculosis genes expressed during macrophage infection.
AuthorsFouad Seghrouchni; Silvia Contini; Roumiana Markova; Roumiana Drenska; Khalid Sadki; Larbi Baassi; Larbii Baassi; Yana Todorova; Velislava Terzieva; Marialuisa Bocchino; Giulia Cappelli; Alfonso Maria Altieri; Mario Giuseppe Alma; Abdelaziz Benjouad; Francesca Mariani; Bogdan Petrunov; Vittorio Colizzi; Rajae El Aouad; Cesare Saltini; Massimo Amicosante
AffiliationsDepartment of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. fseghrouchni@yahoo.fr.
JournalTuberculosis (Edinb)
Year2009
AbstractIn vitro diagnosis of MTB-infection uses MTB-proteins coded for by genes of the region of differentiation 1 (RD1) of the MTB genome. This study wants to test if proteins preferentially expressed during MTB-intracellular growth might provide new targets for the diagnosis of MTB-infection. To this end seventy-five multiepitopic HLA-promiscuous MTB-peptides were designed by quantitative implemented peptide-binding motif analysis from 3 MTB-protein genes expressed in activated human macrophages (MA), 4 genes expressed during growth in non-activated human macrophages (MN-A), 12 housekeeping genes (HKG) and 6 genes of the RD1 region (RD1) as control. ELISpot for IFN-was performed to measure the responses of PBMCs deriving from 45 patients affected by active tuberculosis and 34 controls. In active-TB patients, the mean response to RD1-derived peptides was higher than that to either MA (p<0.01), MN-A (p<0.008) or HKG (p<0.01) derived peptides. In TST-positive subjects all selected peptides elicited significant IFN-T-cell responses (p<0.02 compared to TST-negatives), but without differences between the subgroups. Further, T-cell responses to RD1 peptides were lower in the 23 active-TB treated patients than in the untreated ones (p<0.01). The response to MA peptides in treated active-TB was higher than when untreated (p<0.01). These results demonstrate that the use of in vitro models of MTB-intracellular infection to select MTB gene products for further in silico and in vitro assessment of their immunogenicity have the potential to identify novel antigens amenable to the design of new tools for diagnosis and monitoring of tuberculosis.
Curation Last Updated2023-08-18 20:42:43
Epitope
Epitope ID120875
Chemical TypeLinear peptide
Linear SequencePRVVATVPQLVQLAPHAVQMSQN
Source Molecule Namehypothetical protein
Source OrganismMycobacterium tuberculosis H37Rv (Mycobacterium tuberculosis str. H37Rv)
Starting Position139
Ending Position161
Epitope Reference Details
Epitope Structure DefinesEpitope containing region/antigenic site
Epitope NameKHG peptide 65
Reference Starting Position138
Reference Ending Position160
Location of Data in ReferenceTable 2
Immunization
Host OrganismHomo sapiens (human)
1st In Vivo Process
In Vivo Process TypeOccurrence of infectious disease
Disease Statetuberculosis
Disease StageAcute/Recent onset;OGMS:0000094
1st Immunogen
Epitope RelationTaxonomic Parent
Object TypeOrganism
OrganismMycobacterium tuberculosis
Immunization Comments
Immunization CommentsPBMCs were prepared from patients with active TB.
T Cell Assay
Qualitative MeasurementPositive
Method/TechniqueELISPOT
Measurement ofIFNg release
Effector Cells
Effector Cell Tissue TypeBlood
Effector Cell TypeT cell
Effector Cell Culture ConditionsDirect Ex Vivo
Antigen Presenting Cells
Cell Tissue TypeBlood
Cell TypePBMC
Cell Culture ConditionsDirect Ex Vivo
Antigen
Epitope RelationEpitope
Chemical TypeLinear peptide
Linear SequencePRVVATVPQLVQLAPHAVQMSQN
Source Molecule Namehypothetical protein
Source OrganismMycobacterium tuberculosis H37Rv (Mycobacterium tuberculosis str. H37Rv)
Starting Position139
Ending Position161
Assay Reference Details
Location of Assay Data in ReferenceFigure 1